Lipocine to present lpcn 1148 and lpcn 1144 at the easl congress 2023

Phase 2 proof-of-concept study of lpcn 1148 in male cirrhotic patients with sarcopenia is fully enrolled with topline 24-week results expected mid-2023 salt lake city , june 7, 2023 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company focused on treating central nervous system (cns) disorders by leveraging its proprietary technology platform to develop differentiated products, today announced that it will present posters on lpcn 1148 and lpcn 1144 at the forthcoming european association for the study of the liver (easl) congress 2023, to take place in vienna, austria, june 21 – 24, 2023. a multimodal treatment candidate for sarcopenia in men with decompensated cirrhosis: a randomized, placebo-controlled trial evaluating lpcn 1148 lead author and presenter: dr. benjamin j.
LPCN Ratings Summary
LPCN Quant Ranking